Skip to content

PHARMA BUYL-LOUISE: what changed

BE 0764.926.261NACE 47.730, Retail sale of pharmaceutical productsOther company

Position among the sector peers

What moved between 2024 and 2025

Net result for the year
€72,981
2024 · €71,559+€1,422
Equity
€152,271
2024 · €151,290+€981
Cash
€7,501
2024 · €3,292+€4,209
Balance sheet total
€380,658
2024 · €391,574-€10,916

Largest movements

2024 to 2025
Assets
  • Receivables within one year -€15,125

    down €15,125 (-16.4%), from €92,346 to €77,221

  • Cash +€4,209

    up €4,209 (+128%), from €3,292 to €7,501

    mainly Net result for the year (+€72,981) and Receivables within one year (+€15,125)

Equity and liabilities
  • Debts after one year -€25,009

    down €25,009 (-17.9%), from €139,718 to €114,709

  • Other debts +€13,524

    up €13,524 (+22.9%), from €59,000 to €72,524

Income statement
  • Gross operating margin +€1,346

    up €1,346 (+1.5%), from €92,191 to €93,537

Change in the result, 2024 to 2025

effect on the result

For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.

Result 2024 €71,559
Gross operating margin +€1,346
Financial charges +€422
Taxes -€346
Result 2025 €72,981
raises the resultlowers the result

Derived cash bridge

cash 2024 to 2025

The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.

From operations +€101,844
Investment €0
Financing -€97,635
Cash 2024 €3,292
Net result for the year +€72,981
Receivables within one year +€15,125
Trade debts -€386
Tax, wage and social debts +€630
Other debts +€13,524
Accrued charges and deferred income -€29
Debts after one year -€25,009
Current portion of long-term debt +€374
Short-term financial debts -€1,000
Contributions, distributions and other -€72,000
Cash 2025 €7,501
brings cash intakes cash out
Every line side by side 36 lines
Line Code 2024 2025 Change %
Total assets 20/58 €391,574 €380,658 -€10,916 -2.8%
Fixed assets 21/28 €245,936 €245,936 = 0.0%
Financial fixed assets 28 €245,936 €245,936 = 0.0%
Current assets 29/58 €145,638 €134,722 -€10,916 -7.5%
Amounts receivable after more than one year 29 €50,000 €50,000 = 0.0%
Other amounts receivable 291 €50,000 €50,000 = 0.0%
Amounts receivable within one year 40/41 €92,346 €77,221 -€15,125 -16.4%
Other amounts receivable 41 €92,346 €77,221 -€15,125 -16.4%
Cash at bank and in hand 54/58 €3,292 €7,501 +€4,209 +128%
Total equity and liabilities 10/49 €391,574 €380,658 -€10,916 -2.8%
Equity 10/15 €151,290 €152,271 +€981 +0.6%
Contributions 10/11 €25,000 €25,000 = 0.0%
Profit (loss) carried forward 14 €126,290 €127,271 +€981 +0.8%
Amounts payable 17/49 €240,284 €228,387 -€11,897 -5.0%
Amounts payable after more than one year 17 €139,718 €114,709 -€25,009 -17.9%
Financial debts 170/4 €139,718 €114,709 -€25,009 -17.9%
Amounts payable within one year 42/48 €100,367 €113,509 +€13,142 +13.1%
Current portion of amounts payable after more than one year 42 €26,704 €27,078 +€374 +1.4%
Financial debts 43 €5,833 €4,834 -€1,000 -17.1%
Credit institutions 430/8 €5,833 €4,834 -€1,000 -17.1%
Trade debts 44 €1,279 €893 -€386 -30.2%
Suppliers 440/4 €1,279 €893 -€386 -30.2%
Taxes, remuneration and social security 45 €7,551 €8,181 +€630 +8.3%
Taxes 450/3 €7,551 €8,181 +€630 +8.3%
Other amounts payable 47/48 €59,000 €72,524 +€13,524 +22.9%
Accrued charges and deferred income 492/3 €199 €170 -€29 -14.8%
Gross operating margin 9900 €92,191 €93,537 +€1,346 +1.5%
Operating profit (loss) 9901 €92,191 €93,537 +€1,346 +1.5%
Financial income 75/76B €585 €585 = 0.0%
Recurring financial income 75 €585 €585 = 0.0%
Financial charges 65/66B €3,038 €2,616 -€422 -13.9%
Recurring financial charges 65 €3,038 €2,616 -€422 -13.9%
Profit (loss) for the period before taxes 9903 €89,738 €91,506 +€1,768 +2.0%
Income taxes 67/77 €18,179 €18,525 +€346 +1.9%
Profit (loss) for the period 9904 €71,559 €72,981 +€1,422 +2.0%
Profit (loss) for the period to be appropriated 9905 €71,559 €72,981 +€1,422 +2.0%

Value

latest balance sheet 31-12-2025 · indication, not a valuation or advice

Indicative value of the equity

Indication, not a valuation or advice
€300,450 to €390,175

Midpoint €337,835 · 50% capitalised earnings, 50% adjusted equity

Capitalisation rate 12% result over 3 years earnings weight 50%

Worked out with Checked's starting values, not your estimate and not market data. Change the assumptions: the value follows.

Adjusted equity €152,271
Capitalised earnings €448,629 to €628,080
Indication €300,450 to €390,175

Adjusted equity

balance sheet 31-12-2025
Equity (10/15)
€152,271
Revaluation of assets
€0
Deferred tax on the revaluation
€0
Other adjustment
€0
Adjusted equity
€152,271

Capitalised earnings

net result for the year (9904)
2025
€72,981
2024
€71,559
2023
€43,883
2022
€59,123
2021
€10,724
Average result
€62,808
Divided by the capitalisation rate
14% / 12% / 10%
Capitalised earnings
€448,629 / €523,400 / €628,080

Limits of the indication

  • Checked holds no market prices or comparable transactions.
  • Anything after the latest accounts and items off the balance sheet (guarantees, leases, disputes) are left out.
  • Checked does not know the real value of buildings, stock and receivables. Enter your own revaluation or adjustment for it.
  • The result is not corrected for the manager's pay. If the company pays less or more than a market salary, the capitalised earnings are too high or too low.
  • The owner's role in the business, synergies for a buyer and the tax consequences of a sale are left out.

For a valuation to base a decision on, go to a company auditor or a certified accountant.

Calculation and sources

Source: filed annual accounts (NBB) and main activity (KBO). The movements compare the financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. The value is an indication, not a valuation or advice. Prepared on 19 November 2026 via checked.be.